DD203071A5 - Verfahren zur herstellung von rekombinant-dna-molekuele - Google Patents

Verfahren zur herstellung von rekombinant-dna-molekuele Download PDF

Info

Publication number
DD203071A5
DD203071A5 DD81243403A DD24340381A DD203071A5 DD 203071 A5 DD203071 A5 DD 203071A5 DD 81243403 A DD81243403 A DD 81243403A DD 24340381 A DD24340381 A DD 24340381A DD 203071 A5 DD203071 A5 DD 203071A5
Authority
DD
German Democratic Republic
Prior art keywords
sequences
hif
dha
sequence
pst
Prior art date
Application number
DD81243403A
Other languages
German (de)
English (en)
Inventor
Charles Weissmann
Original Assignee
Biogen Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27224760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD203071(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Nv filed Critical Biogen Nv
Publication of DD203071A5 publication Critical patent/DD203071A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y10S435/839—Bacillus subtilis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DD81243403A 1980-01-08 1981-01-08 Verfahren zur herstellung von rekombinant-dna-molekuele DD203071A5 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP80300079 1980-01-08
EP80301100 1980-04-03
GB8031737 1980-10-02

Publications (1)

Publication Number Publication Date
DD203071A5 true DD203071A5 (de) 1983-10-12

Family

ID=27224760

Family Applications (2)

Application Number Title Priority Date Filing Date
DD81226884A DD159782A5 (de) 1980-01-08 1981-01-08 Verfahren zur herstellung eines eine immunologische oder biologische aktivitaet von humanleukozyten-interferon aufweisendes polypeptids
DD81243403A DD203071A5 (de) 1980-01-08 1981-01-08 Verfahren zur herstellung von rekombinant-dna-molekuele

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DD81226884A DD159782A5 (de) 1980-01-08 1981-01-08 Verfahren zur herstellung eines eine immunologische oder biologische aktivitaet von humanleukozyten-interferon aufweisendes polypeptids

Country Status (22)

Country Link
EP (1) EP0032134B2 (pt)
JP (1) JP2501889B2 (pt)
AU (1) AU553400B2 (pt)
CA (1) CA1341567C (pt)
CY (1) CY1346A (pt)
DD (2) DD159782A5 (pt)
DE (1) DE3165463D1 (pt)
DK (2) DK170236B1 (pt)
ES (2) ES8308534A1 (pt)
FI (1) FI86558C (pt)
GR (1) GR73557B (pt)
HU (1) HU194305B (pt)
IE (1) IE54096B1 (pt)
MY (1) MY8700559A (pt)
NO (2) NO164037C (pt)
NZ (1) NZ195980A (pt)
OA (1) OA06717A (pt)
PH (1) PH21848A (pt)
PL (1) PL148434B1 (pt)
PT (1) PT72322B (pt)
SG (1) SG77286G (pt)
YU (1) YU45533B (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
IE57069B1 (en) 1980-04-03 1992-04-22 Biogen Inc Dna sequences,recombinant dna molecules and processes for producing human fibroblast interferon
EP0042246B1 (en) * 1980-06-12 1987-03-18 The Cancer Institute Of Japanese Foundation For Cancer Research Plasmid
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
EP0062971B1 (en) * 1981-03-27 1990-03-07 Imperial Chemical Industries Plc Genetically modified microorganisms
WO1983000693A1 (en) * 1981-08-14 1983-03-03 Berg, Kurt, Frimann SUBJECTS RELATING TO HUMAN INTEFERON-'alpha' SUBTYPE PROTEINS AND CORRESPONDING ANTIBODIES
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
US5098703A (en) * 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
US4973479A (en) * 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
US4975276A (en) * 1982-01-15 1990-12-04 Cetus Corporation Interferon-alpha 54
US5827694A (en) * 1982-03-08 1998-10-27 Genentech, Inc. DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
DE3220116A1 (de) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
US4892743A (en) * 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
US5231176A (en) * 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
ATE47864T1 (de) * 1984-08-27 1989-11-15 Genentech Inc Verschiedenartige familie von menschlichen leukozyten-interferonen, zusammensetzungen, die diese enthalten, verfahren zu ihrer herstellung, sowie dna und transfektierte wirte hierfuer.
IL76360A0 (en) * 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
EP0194006B1 (en) * 1985-02-01 1992-04-29 Imperial Chemical Industries Plc Analogous interferon polypeptides, process for their preparation and pharmaceutical compositions containing them
SE8502430L (sv) * 1985-05-15 1986-11-16 Kabivitrum Ab En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
DE3688920T4 (de) * 1985-07-03 1995-08-31 Genencor Int Hybride Polypeptide und Verfahren zu deren Herstellung.
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
DE3751409T2 (de) 1986-04-15 1996-01-25 Ciba Geigy Ag Monoklonale Antikörper gegen Interferon-induziertes humanes Protein in gereignigter Form, und diese Antikörper enthaltende Testsätze.
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US5190751A (en) * 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5256410A (en) * 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
IL136326A0 (en) 1997-12-08 2001-05-20 Genentech Inc Human interferon-epsilon: a type i interferon
ZA9811070B (en) 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
CZ303110B6 (cs) 1998-11-12 2012-04-04 Schering Corporation Zpusob zvýšení výtežku prostredku obsahujícího interferon alfa
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
AU2001255380A1 (en) * 2000-04-14 2001-10-30 Zymogenetics Inc. Human interferon, zinf2
EP1939293A3 (en) * 2000-06-30 2008-07-09 ZymoGenetics, Inc. Interferon-Like Protein ZCYTO21
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
EP1942187B1 (en) * 2001-04-20 2010-09-22 ZymoGenetics, L.L.C. Cytokine protein family
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
FR2824333B1 (fr) 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1575609A4 (en) 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
WO2004039996A1 (en) * 2002-11-01 2004-05-13 Cadila Healthcare Limited Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
US20050244423A1 (en) 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
WO2006095433A1 (ja) * 2005-03-10 2006-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo ウシの消化器疾患治療剤
CA2616004A1 (en) 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
EP2207890A4 (en) 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
AU2009330278B2 (en) 2008-12-23 2013-01-31 Merck Sharp & Dohme Corp. Purification of recombinantly produced interferon
WO2019226050A2 (en) * 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862495D1 (en) * 1977-11-08 1989-05-24 Genentech Inc Plasmid for transforming bacterial host to render it capable of polypeptide expression
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna

Also Published As

Publication number Publication date
DD159782A5 (de) 1983-04-06
PL148434B1 (en) 1989-10-31
YU2681A (en) 1983-12-31
ES498343A0 (es) 1983-09-01
JPH02131431A (ja) 1990-05-21
NZ195980A (en) 1984-10-19
IE810025L (en) 1981-07-08
DK170236B1 (da) 1995-07-10
EP0032134A2 (en) 1981-07-15
FI810030L (fi) 1981-07-09
NO810041L (no) 1981-07-09
JP2501889B2 (ja) 1996-05-29
ES509222A0 (es) 1983-11-01
YU45533B (en) 1992-05-28
PL229123A1 (en) 1983-07-18
DK5681A (da) 1981-07-09
ES8400770A1 (es) 1983-11-01
EP0032134B2 (en) 1993-10-13
DE3165463D1 (en) 1984-09-20
EP0032134A3 (en) 1981-08-26
NO164037B (no) 1990-05-14
AU6605781A (en) 1981-07-30
ES8308534A1 (es) 1983-09-01
HU194305B (en) 1988-01-28
FI86558C (fi) 1992-09-10
FI86558B (fi) 1992-05-29
CA1341567C (en) 2008-02-19
NO850733L (no) 1981-07-09
PT72322A (en) 1981-03-01
CY1346A (en) 1987-01-16
GR73557B (pt) 1984-03-15
PT72322B (en) 1982-09-23
DK61595A (da) 1995-05-31
MY8700559A (en) 1987-12-31
AU553400B2 (en) 1986-07-17
PH21848A (en) 1988-03-17
OA06717A (fr) 1982-06-30
EP0032134B1 (en) 1984-08-15
IE54096B1 (en) 1989-06-21
NO164037C (no) 1990-08-22
SG77286G (en) 1987-02-27

Similar Documents

Publication Publication Date Title
DD203071A5 (de) Verfahren zur herstellung von rekombinant-dna-molekuele
DD160280A5 (de) Verfahren zur herstellung eines eine immunologische oder biologische aktivitaet von humanfibroblast-interferon aufweisenden polypeptids
DE3177298T2 (de) Verbesserte vektoren, verfahren zur herstellung solcher vektoren und zur expression von klonierten genen.
DE3586189T2 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
DE3020528C2 (pt)
EP0099084B1 (de) Verfahren zur Herstellung von Interferon und Expressionsvektoren dafür
DE3685996T2 (de) Hybrid-interferone.
DE3072205T2 (de) Dns-transfer-vektor, damit transformierter wirt, impfstoff und ihre herstellung.
EP0076489B1 (de) Desoxyribonucleinsäuren, rekombinante Desoxyribonucleinsäuren, sie enthaltende Wirte, Polypeptide und Verfahren zu ihrer Herstellung
DE3382575T2 (de) Dna-sequenzen, rekombinante dna-molekuele und verfahren zur herstellung von schweinewachstumshormonaehnlichen polypeptiden.
DD203330A5 (de) Verfahren zur herstellung hybrider human-leukozyten-interferone
CH663032A5 (de) Doppelstraengige dna, replizierbare plasmidische expressionstraeger zur mikrobiellen herstellung von hybrid human-leukozyten-interferon und transformierte mikroorganismen.
DD216044A5 (de) Verfahren zur herstellung eines rekombinierenden dna-klonierungsvektors
DD209652A5 (de) Verfahren zur herstellung eines replikablen vektors
CH684892A5 (de) DNA, welche für ein Polypeptid mit der Aktivität von menschlichem Interferon und beta 2 kodiert und Verfahren zu dessen Herstellung.
DD208822A5 (de) Verfahren zur herstellung eines polypeptids, das im wesentlichen aus der aminosaeuresequenz von reifem human-immuninterferon besteht
DE3308030A1 (de) Tierische interferone
DD246318A5 (de) Neue genetische Sequenzen, die durch die codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
CH675731A5 (pt)
DD160279A5 (de) Verfahren zur herstellung eines die spezifitaet von mks-virus-antigenen aufweisenden polypeptits
DE69618574T2 (de) Vom desmingen abstammende amplifizierungssequenzen, vektoren, die diese enthalten und anwendungen derselben zur herstellung von proteinen
DE3103714A1 (de) Dns-rekombinationsverfahren zur herstellung eines dem menschlichen interferon aehnlichen proteins
AT394209B (de) Verfahren zur herstellung neuer mikroorganismen zur produktion von hybriden human-leukozyten-interferonen
DE3686148T2 (de) Lymphotoxin-gen, verfahren zu dessen herstellung und lymphotoxin.
DE3689993T2 (de) Vektor für Expression und Sekretion von Produkten von heterologen Genen in Bacillus Subtilis.